P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy

JCO Precis Oncol. 2020:4:152-160. doi: 10.1200/PO.19.00294. Epub 2020 Mar 5.

Authors

Umut Aypar¹, Justin Taylor², Jacqueline S Garcia³, Amir Momeni-Boroujeni¹, Qi Gao¹, Jeeyeon Baik¹, Dory Londono¹, Ryma Benayed¹, Allison Sigler¹, Michael Haddadin², Alexander V Penson², Maria E Arcila¹, Kerry Mullaney¹, Purvil Sukhadia¹, Andres E Quesada¹, Mikhail Roshal¹, Nicole Cullen⁴, Ana Lako⁴, Scott J Rodig⁴, Aaron D Goldberg², Yanming Zhang¹, Wenbin Xiao¹, Caleb Ho¹

Affiliations

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

No abstract available

Keywords: AML; CTLA-4 antagonist; P2RY8-CRLF2 fusion; immunotherapy.

Grants and funding